US Penny Stocks To Watch In January 2025

In This Article:

As the U.S. stock market navigates mixed performance amid fluctuating interest rate expectations and economic data releases, investors are keenly observing potential opportunities in various sectors. Penny stocks, often representing smaller or emerging companies, continue to attract attention due to their potential for significant value creation when supported by strong financials. Despite being an older term, penny stocks remain relevant for those seeking to uncover promising investments in less-established firms with robust growth prospects.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.81

$5.79M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.25

$1.93B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$100.69M

★★★★★★

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.7257

$11.81M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.32

$11.77M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.41

$46.86M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.49

$44.59M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.37

$28.91M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.97

$91.74M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.45

$365.18M

★★★★☆☆

Click here to see the full list of 727 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Lisata Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for solid tumors and other diseases, with a market cap of $31.31 million.

Operations: Lisata Therapeutics, Inc. currently does not report any revenue segments.

Market Cap: $31.31M

Lisata Therapeutics is a pre-revenue company with a market cap of US$31.31 million, focusing on innovative cancer therapies. Recent strategic moves include a collaboration with Kuva Labs for advanced imaging agents and the completion of patient enrollment in its CENDIFOX trial, which could enhance its research capabilities. Despite being debt-free and having sufficient cash runway for over a year, Lisata remains unprofitable with earnings forecasted to decline by 3.2% annually over the next three years. Shareholder dilution has occurred recently, but short-term assets comfortably cover liabilities, indicating financial stability amidst ongoing challenges in achieving profitability.

NasdaqCM:LSTA Debt to Equity History and Analysis as at Jan 2025
NasdaqCM:LSTA Debt to Equity History and Analysis as at Jan 2025

CollPlant Biotechnologies

Simply Wall St Financial Health Rating: ★★★★★☆


Waiting for permission
Allow microphone access to enable voice search

Try again.